Bio-Rad Labs (BIO) Tops Q4 EPS by 4c; offers outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts BIO Hot Sheet
EPS Growth %: -1.3%
Financial Fact:
Net income attributable to Bio-Rad: 18.01M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Bio-Rad Labs (NYSE: BIO) reported Q4 EPS of $2.90, $0.04 better than the analyst estimate of $2.86. Revenue for the quarter came in at $667.5 million versus the consensus estimate of $681.29 million.
Full-Year 2025 Financial Outlook
Bio-Rad is providing its financial outlook for the full year 2025. The company currently expects non-GAAP, currency-neutral revenue growth of approximately 1.5 to 3.5 percent and an estimated non-GAAP operating margin of approximately 13.0 to 13.5 percent.
For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Chemung Financial (CHMG) Tops Q3 EPS by 69c
- Eagle Financial Services, Inc. (EFSI) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
